SANES

10.158

-0.37%↓

BBVA

18.805

-0.66%↓

BNP

89.3

-2.98%↓

CABK

10.93

-0.41%↓

INGA

25.325

-2.45%↓

SANES

10.158

-0.37%↓

BBVA

18.805

-0.66%↓

BNP

89.3

-2.98%↓

CABK

10.93

-0.41%↓

INGA

25.325

-2.45%↓

SANES

10.158

-0.37%↓

BBVA

18.805

-0.66%↓

BNP

89.3

-2.98%↓

CABK

10.93

-0.41%↓

INGA

25.325

-2.45%↓

SANES

10.158

-0.37%↓

BBVA

18.805

-0.66%↓

BNP

89.3

-2.98%↓

CABK

10.93

-0.41%↓

INGA

25.325

-2.45%↓

SANES

10.158

-0.37%↓

BBVA

18.805

-0.66%↓

BNP

89.3

-2.98%↓

CABK

10.93

-0.41%↓

INGA

25.325

-2.45%↓

Home・Aandelen Lijst・DBV Technologies SA

D
DBV Technologies SA

Gesloten

3.364 -0.53

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.35

Max

3.472

Belangrijke statistieken
By Trading Economics
Inkomsten	-2.4M -48M
Winstmarge	-1,323.179
Werknemers	161
EBITDA	-4.1M -46M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	-3.55% downside

Dividenden
By Dow Jones
Volgende Winsten	29 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-7.7M 1B
Vorige openingsprijs	3.89
Vorige sluitingsprijs	3.364

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

1.61 / 1.72 Steun & Weerstand

DBV Technologies SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 mei 2026, 22:47 UTC

Populaire aandelen

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mei 2026, 22:16 UTC

Acquisities, Fusies, Overnames

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mei 2026, 22:00 UTC

Belangrijke Marktbewegers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mei 2026, 18:09 UTC

Belangrijke Marktbewegers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 mei 2026, 16:02 UTC

Winsten

Belangrijke Marktbewegers

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 mei 2026, 14:55 UTC

Belangrijke Marktbewegers

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 mei 2026, 14:43 UTC

Belangrijke Marktbewegers

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 mei 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:59 UTC

Acquisities, Fusies, Overnames

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mei 2026, 21:50 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mei 2026, 21:16 UTC

Marktinformatie

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 mei 2026, 20:19 UTC

Populaire aandelen

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mei 2026, 19:41 UTC

Acquisities, Fusies, Overnames

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mei 2026, 19:35 UTC

Marktinformatie

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mei 2026, 19:33 UTC

Marktinformatie

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mei 2026, 18:35 UTC

Winsten

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 mei 2026, 17:28 UTC

Marktinformatie

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 mei 2026, 16:50 UTC

Acquisities, Fusies, Overnames

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 mei 2026, 16:24 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 mei 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

15 mei 2026, 16:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 mei 2026, 15:55 UTC

Marktinformatie

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 mei 2026, 15:20 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 mei 2026, 15:20 UTC

Marktinformatie

Silver Plunges on Inflation Worries -- Market Talk

15 mei 2026, 15:20 UTC

Winsten

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 mei 2026, 14:33 UTC

Marktinformatie

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Peer Vergelijking

Prijswijziging

DBV Technologies SA Prognose

Koersdoel

By TipRanks

-3.55% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.26 EUR -3.55%

Hoogste 5.5 EUR

Laagste 1.01 EUR

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor DBV Technologies SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan DBV Technologies SA - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.61 / 1.72Steun & Weerstand

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over DBV Technologies SA

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.